Multiple myeloma/hypercalcemia by Oyajobi, Babatunde O
Page 1 of 6
(page number not for citation purposes)
Available online http://arthritis-research.com/content/9/S1/S4
Abstract
Multiple myeloma, a cancer of plasma cells, is associated with
excessive tumor-induced, osteoclast-mediated bone destruction.
Hypercalcemia remains the most frequent metabolic complication
of myeloma in patients, and excessive osteolysis plays a major
contributory role in its pathogenesis. The clinical presentation of
hypercalcemia in patients varies depending on the level of ionized
calcium; it can be life threatening, as in the case of hypercalcemic
crisis, requiring immediate medical treatment to prevent death.
During the past few years there have been exciting developments
in our understanding of the pathogenesis of myeloma bone
disease; in particular, key mediators of the osteoclastic bone
resorption in myeloma have been identified, including receptor
activator of nuclear factor-κB ligand (RANKL) and macrophage
inflammatory protein-1α. There is also increasing evidence that
Dickkopf 1, which has been shown to be over-expressed in
myeloma patients, is also a potent stimulator of osteoclast
formation and activity. Importantly, the available data suggest that
RANKL is the final common mediator of osteoclastic bone
resorption, irrespective of the upstream initiator molecule. This brief
review presents an overview of the roles played by these mediators
in inducing osteolysis in myeloma bone disease, and it discusses
targeting RANKL as a potential new treatment strategy in myeloma
bone disease and myeloma-associated hypercalcemia.
Introduction
Multiple myeloma, a clonal neoplasm of plasma cells, is the
second most common adult hematologic malignancy, and it is
the most common cancer with skeleton as its primary site.
Multiple myeloma, which affects 70,000 people in the USA,
with 15,000 new cases accruing yearly, accounts for 1% to
2% of cancer-related deaths. Myeloma is unique in its
propensity to cause osteolysis, with 80% of patients suffering
from devastating and progressive bone destruction; this
results in the complications that are responsible for the high
morbidity and mortality rates associated with the disease.
These complications, which include severe and unremitting
bone pain, pathologic fractures (Figure 1), spinal cord
compression, and hypercalcemia, are a significant clinical
problem for which there is no effective cure. Hypercalcemia,
which can range in presentation from mild to severe and life
threatening, is the most common metabolic complication of
myeloma and occurs in approximately one-third of patients.
Hypercalcemia in myeloma
In myeloma patients, the primary cause of the hypercalcemia is
widespread tumor-induced bone destruction. This is primarily
due to increased osteoclastic bone resorption caused by
potent cytokines expressed or secreted locally by the myeloma
cells (receptor activator of nuclear factor-κB ligand [RANKL],
macrophage inflammatory protein [MIP]-1α, and tumor
necrosis factors [TNFs]; see below) or over-expressed by other
cells in the local microenvironment [1]. This bone resorption in
turn leads to efflux of calcium into the extracellular fluid.
However, the pathogenesis of hypercalcemia in myeloma is
probably more complex than this because not all patients with
significant myeloma bone disease develop hypercalcemia and,
even in the patients who do develop it, hypercalcemia is often a
prominent feature only late in the course of disease.
Hypercalcemia is most common in those myeloma patients
who have the greatest tumor volume, irrespective of serum
parathyroid hormone-related protein (PTHrP) status. The
reasons for this are still unclear but they may be related to the
amount of bone-resorbing activity produced by myeloma cells
as well as glomerular filtration status. Because myeloma
patients often have irreversible impairment in renal function
and increased renal tubular calcium reabsorption, the
capacity of the kidneys to clear excess calcium load from the
circulation effectively is overwhelmed, resulting in elevated
serum calcium levels. Elevated serum PTHrP is not a
consistent finding in myeloma patients, and it remains unclear
why myeloma patients present with increased renal tubular
calcium reabsorption. Consistent with this, hypercalcemia is
more frequent in patients with plasma cell leukemia, a late
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stage complication of myeloma, than in overt myeloma per se
[2], despite the fact that plasma cell leukemias induce
comparatively weaker bone-resorbing activity. This is a
consequence of the severe renal insufficiency associated with
plasma cell leukemia. Measurements of total body myeloma cell
burden together with production of bone-resorbing activity by
cultured bone marrow myeloma cells in vitro do not correlate
closely with hypercalcemia, although they do correlate
somewhat with the extent of osteolytic bone lesions [3]. Thus,
other factors are probably involved in the pathogenesis of
hypercalcemia, in addition to those that promote osteoclast
formation and induce osteoclast activation.
There are other differences between the hypercalcemia that
occurs in myeloma and classical humoral hypercalcemia of
malignancy in patients with solid tumors. First, in contrast to
myeloma patients with hypercalcemia, in which PTHrP is
implicated only sporadically, humoral hypercalcemia of
malignancy is almost always due to excessive secretion of
PTHrP by the tumor, resulting in elevated circulating levels.
Second, in patients with hypercalcemia due to myeloma,
there is almost always impaired renal function and increased
serum phosphate that is associated with decreased
glomerular filtration rate. Third, markers of bone formation
such as serum alkaline phosphatase are commonly not
elevated in patients with myeloma, because bone formation is
often not altered and may in fact be suppressed for reasons
that are not entirely clear but may involve Dickkopf (DKK)1
(see below). Finally, patients with hypercalcemia due to
myeloma usually respond very rapidly to treatment with
corticosteroids, mainly because of their rapid suppression of
myeloma tumor growth, unlike patients with humoral hyper-
calcemia caused by solid tumors [4].
Myeloma bone disease
The excessive bone destruction that is characteristic of multiple
myeloma is dependent on osteoclast stimulation. Although it
has been known for more than three decades that osteoclasts
are hyperstimulated by cytokines in myeloma, the osteoclast-
activating factors (OAFs) responsible proved elusive until the
late 1990s. For some time the erstwhile approach of
identifying such factors by use of cultured tumor cell lines,
followed by protein purification, was unsuccessful. It is now
apparent that cell-cell interactions involving myeloma cells and
other cells in the marrow microenvironment, including stromal
cells, cells of the osteoblast lineage, and possibly osteoclasts
themselves, are required for production of OAFs in myeloma.
There is now abundant evidence that the OAFs that are
probably responsible for bone resorption in myeloma are the
cytokine RANKL and the chemokine MIP-1α. However, a
number of other cytokines, including TNF-α, lymphotoxin
(TNF-β), and PTHrP, have also been implicated in the disease.
There is still considerable debate as to whether in myeloma
these bone-resorbing cytokines are produced by the tumor
cells or accessory cells involved in cell-cell interactions, or
both; indeed, there is evidence in support of both notions.
RANKL
RANKL is part of a system of TNF ligand and receptor
superfamily members that include its cognate signaling
receptor RANK (receptor activator of nuclear factor-κB) and
the decoy receptor antagonist osteoprotegerin (OPG), which
regulate osteoclastogenesis and bone resorption in vivo.
Both RANKL and OPG are expressed by bone marrow
stromal cells (BMSCs) and osteoblasts. It is now well
established that RANKL is increased and OPG is markedly
decreased in bone marrow in multiple myeloma. Early studies
demonstrated that co-culture of myeloma cells and BMSCs
leads to marked induction of RANKL expression by both cell
types, and a concomitant downregulation of OPG expression
by BMSCs [5]; this illustrates the importance of interactions
between myeloma cells and stromal cells. This induction of
RANKL and downregulation of OPG in myeloma cell-BMSC
co-cultures is abrogated by neutralizing antibody to α4
integrin receptor subunit, and treatment of myeloma tumor
cells with a recombinant soluble form of vascular cell
adhesion molecule (VCAM)-1 (a ligand for the α4 adhesion
molecule) was sufficient to induce RANKL expression [5].
These data suggest that cell-cell interactions, mediated by
stromal cell expressed VCAM-1 binding to very late antigen-4
(α4β1 integrin) on myeloma cells, are necessary for tumor
cells to express RANKL.
Figure 1
Osteolytic lesions and pathologic fracture in a 76-year-old female
myeloma patient. With permission from Nair and Pearson [45].
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These findings of RANKL induction and concomitant OPG
downregulation in bone-derived cells in myeloma were
subsequently replicated in other studies involving myeloma
cell-BMSC and myeloma cell-osteoblast co-cultures [6,7],
although these latter studies and others did not observe an
increase in RANKL expression in tumor cells [8]. However,
evidence is accumulating that supports the notion that
myeloma cells themselves also express RANKL, thus
providing a mechanism for direct stimulation of osteoclast
formation by myeloma cells [9-13]. Nevertheless, irrespective
of whether myeloma cells themselves are capable of driving
osteoclastogenesis in myeloma directly, it is incontrovertible
that RANKL is over-expressed in the marrow micro-
environment in myeloma patients, with the ratio of RANKL to
OPG markedly upregulated as compared with that in normal
control individuals [14].
Data from a number of studies have shown that neutralizing
the biologic effects of this over-expressed RANKL in vivo,
using either a genetically engineered soluble form of RANK
(RANK-Fc) or OPG-Fc, reduces bone destruction and has a
beneficial effect in murine models of myeloma bone disease
[6,15-17]. These chimeric molecules act as decoys by
binding to and sequestering RANKL, thus preventing it from
interacting with its native receptor on hematopoietic
osteoclast precursors and mature osteoclasts. As proof of
principle that targeting the RANKL/RANK system is beneficial
in hypercalcemia, RANK-Fc (constructed by fusing the
extracellular domain of murine RANK to the Fc region of
human lgG1) was found to inhibit normal and pathologic
osteoclastic bone resorption in a mouse model of tumor-
induced hypercalcemia [18]. Importantly, neutralizing mono-
clonal antibodies raised against the mouse α4 integrin
subunit also decreased osteolysis and overall tumor burden
in a mouse model of myeloma bone disease [19]. The latter
finding is consistent with the notion that RANKL levels are
modulated by stromal cell-expressed VCAM-1 binding to very
late antigen-4 on myeloma tumor cells [5]. Taken together,
the available data strongly suggest that RANKL is not only the
final common mediator of osteoclast activation but also that it
is a myeloma cell product, and that aberrant expression of
this cytokine within the myeloma marrow millieu is likely to be
pivotal in initiating and maintaining the characteristic bone
destruction as well as promoting hypercalcemia.
Unlike most of the other mediators previously implicated in
myeloma bone disease, RANKL is expressed in various cell
types as a transmembrane protein, although it can be
cleaved, as occurs in activated T cells, to yield a soluble form
that remains biologically active. Unlike for T cells, however,
there is no unequivocal evidence to date that ‘soluble
RANKL’ in myeloma is either naturally secreted or cleaved
from the cell surface by a proteinase. Nevertheless, whether
the predominant source of RANKL in the myeloma bone
microenvironment is tumor cells or BMSCs, or both, the
consequent exaggerated osteoclast formation and activation
is likely to be exacerbated by a concomitant decrease in
locally available OPG. The reduced levels of OPG in bone
marrow of patients with myeloma is likely to be further
exarcebated by binding, internalizing, and degrading of OPG
by tumor cells [20]. Consistent with this, serum OPG levels in
myeloma patients are significantly reduced compared with
those in healthy control individuals [21].
Macrophage inflammatory protein-1α α
MIP-1α is a member of the C-C chemokine family produced
by myeloma cells and has been implicated as an important
mediator in myeloma bone disease that stimulates osteoclast
formation and differentiation, and bone resorption [22-27].
Consistent with the notion that it plays an important role in
the pathogenesis of myeloma-associated osteolysis in vivo,
there is now convincing evidence, in RANK knockout mice,
that MIP-1α also stimulates osteoclast differentiation and
bone resorption in vivo in a RANKL/RANK-dependent
manner when it is expressed adjacent to bone surfaces [22].
MIP-1α is present in bone marrow and marrow supernatants
of patients with myeloma bone disease at much higher levels
than in patients with other hematologic malignancies and in
normal control individuals [23]. Furthermore, its levels
correlate with presence of lytic lesions as well as disease
stage and activity [24,25]. MIP-1α was also found to be
elevated in the serum of myeloma patients with severe bone
disease and  correlated positively with bone resorption
markers, providing evidence for a causal role of the chemokine
in the development of lytic bone lesions in myeloma [26,27].
Interestingly, MIP-1α is also produced by osteoblast-like cells
in response to stimulation by interleukin-1 and TNF-α [28].
Because myeloma cells secrete high levels of both cytokines
constitutively [29], this would serve to amplify further the
concentrations of the chemokine locally in the bone micro-
environment. In addition, MIP-1α signaling through cell
surface receptors for MIP-1α (C-C chemokine receptor
[CCR]-1 and CCR5) on bone cells enhances adhesive
interactions between myeloma and marrow stromal cells.
This, in turn, upregulates levels of expression of RANKL and
interleukin-6, which further exacerbates bone destruction and
increases tumor burden [30]. Systemic administration of
neutralizing antibodies to MIP-1α or small molecule CCR-1-
specific and CCR-5-specific antagonists inhibited tumor-
induced osteolysis and limited disease progression in mouse
models of myeloma bone disease [22,31]. Therefore, the
MIP-1α and its cognate receptors may serve as targets for
the development of novel therapies to combat hypercalcemia.
In this regard, MIP-1α has been reported to induce severe
hypercalcemia in other hematopoietic malignancies [32].
Dickkopf 1
DKK1, the prototypic member of a family of proteins that act
as extracellular antagonists of canonical Wnt signaling, is
expressed in bone in osteoblasts, osteocytes, and BMSCs. It
was identified on cDNA microarrays as being preferentially
Available online http://arthritis-research.com/content/9/S1/S4and abundantly expressed in bone marrow aspirates from
patients with myeloma. Specifically, DKK1 over-expression
was reported to be associated with the presence of focal
lesions detected on magnetic resonance imaging [33]. These
data have led to the notion that DKK1 is one of the major
mediators of the osteolysis that occurs in myeloma bone
disease. Interestingly, canonical Wnt signaling was recently
shown to modulate RANKL and OPG expression in osteo-
blasts  in vitro, resulting in inhibition of osteoclastogenesis
[34]. Consistent with these observations, it was recently
reported that DKK1 enhances osteoclast formation and bone
resorption in vitro [35], and systemic administration of anti-
DKK1 antibodies was shown to block osteoclast formation in
vivo in a murine model of myeloma bone disease [36].
Diagnosis and treatment of hypercalcemia
The diagnosis of hypercalcemia is based on concentration of
ionized calcium, because the serum calcium level may be
erroneously low due to binding of circulating calcium to albumin.
The clinical presentation is frequently dependent on the calcium
level; patients may be asymptomatic (≤3 mmol/l) or they may
present with symptoms such as dry mouth, anorexia and
vomiting, polyuria, polydipsia, depression, or confusion (3 to
4 mmol/l). Occasionally, patients may develop a life-threatening
‘hypercalcemic crisis’ (≥4 mmol/l) and present in coma.
The best therapy for myeloma-associated hypercalcemia is,
by and large, successful elimination of the primary tumor, but
myeloma remains an incurable cancer and its unique
propensity to cause bone destruction is, in part, responsible
for the associated hypercalcemia observed in some patients.
Over the past decade, saline replenishment and bisphos-
phonates, which are potent inhibitors of osteoclastic bone
resorption, have become the mainstay of treatment for
cancer-induced osteolytic bone disease and management of
PTHrP-mediated humoral hypercalcemia of malignancy, as
well as hypercalcemia induced by myeloma [37]. In myeloma
patients with hypercalcemia, these agents are usually used in
combination regimens that include corticosteroids and/or
calcitonin, the latter being effective in patients at high risk for
developing a hypercalcemic crisis. The available bisphos-
phonates, including clodronate (a first-generation bisphos-
phonate), pamidronate (a second-generation bisphospho-
nate), and zoledronic acid and ibandronate (third-generation
bisphosphonates), have exhibited varying degrees of efficacy
in multiple clinical trials, undoubtedly influenced by tolerance
or toxicity issues. Orally administered clodronate has
exhibited little ability to slow the development of skeletal
complications in patients. In contrast, oral administration of
the more potent ibandronate or intravenous infusions of either
pamidronate or zoledronic acid have reduced skeletal
complications in patients with cancer-induced bone diseases,
with zoledronic acid being the most effective to date [38-40].
The exciting discovery that the RANKL/RANK/OPG pathway
is indispensable not only for normal bone resorption but also
for pathologic bone resorption and hypercalcemia induced by
myeloma and other cancers that metastasize to the skeleton
has spurred the clinical development of a number of other
types of new antiresorptive agents. Available data from
preclinical and clinical studies strongly suggesting that
RANKL is the final common mediator in tumor-induced bone
destruction that precedes malignancy-associated hyper-
calcemia, irrespective of the upstream initiator, provide a
rationale for pursuing this therapeutic strategy.
Interestingly, data from preclinical studies in murine models of
humoral hypercalcemia of malignancy suggest that inhibition of
RANKL, using OPG-Fc, causes greater suppression of bone
resorption and hypercalcemia than do bisphosphonates [41].
Although its development has been discontinued, AMGN-0007,
a recombinant OPG construct, was shown in early studies to be
efficacious in patients with multiple myeloma or breast cancer
related skeletal metastases. At present, the most advanced anti-
RANKL approach in clinical development is a fully human
monoclonal antibody to RANKL, namely denosumab (Amgen
Inc., Thousand Oaks, CA, USA). Clinical trials with denosumab
are ongoing in patients with multiple myeloma and recent data
suggest that it is efficacious [42]. In addition, studies are
underway in bone metastases from breast cancer, prostate
cancer, and other solid tumors [43].
The observation that an intact RANK signaling pathway is
indispensable for the osteoclastogenic effect of MIP-1α in vivo
[22] lends further support to the notion that RANKL is indeed
the final common mediator of the excessive osteoclast number
and activity in myeloma. It also suggests that denosumab may
be effective in treating hypercalcemia, irrespective of its cause.
With regard to targeting MIP-1α or its receptors, available
preclinical data provide a basis for further studies to determine
the efficacy of orally bioavailable small molecule synthetic
antagonists of the receptors that mediate the effects of MIP-1α
(CCR-1 and CCR-5), as adjuncts to current standard
therapeutic approaches in myeloma-induced hypercalcemia.
Although it is presently unclear which of the MIP-1α signaling
receptors mediates its osteoclastogenic activity, small
molecule antagonists of both CCR-1 and CCR-5 are currently
under development for other disease conditions [44].
Finally, a small molecule (IIC3; Enzo Biochem) that is capable
of binding to and thereby inhibiting the biologic activity of
DKK1 is also currently under development. Given the recently
discovered role of canonical Wnt signaling in osteoclast
formation and the osteoclastogenic effect of DKK1, further
insights into the mechanisms involved in modulating the
effects of DKK1 in myeloma bone disease will help to define
other novel molecular targets, facilitating development of new
therapies for the treatment of associated hypercalcemia.
Conclusion
Hypercalcemia is the most common metabolic complication
of multiple myeloma but its pathogenesis remains unclear.
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such as RANKL, MIP-1α and DKK1 in the exaggerated
osteoclastic bone resorption that characterizes myeloma
bone disease, with compelling evidence for RANKL being the
final common mediator. Given that the increased osteolysis
contributes to the development and progression of hyper-
calcemia in patients, strategies targeting these molecules and
the signaling pathways involved may result in novel therapies
to manage this distressing and often life-threatening
complication of myeloma bone disease.
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